Workflow
广生堂(300436) - 2017 Q3 - 季度财报
CosunterCosunter(SZ:300436)2017-10-26 16:00

Financial Performance - Operating revenue decreased by 6.95% to CNY 72,550,329.09 for the current period, and by 1.99% to CNY 222,740,815.96 year-to-date[8] - Net profit attributable to shareholders decreased by 88.29% to CNY 2,167,935.28 for the current period, and by 50.34% to CNY 29,427,791.37 year-to-date[8] - Basic earnings per share dropped by 88.43% to CNY 0.0153 for the current period, and by 51.00% to CNY 0.2074 year-to-date[8] - The weighted average return on equity decreased to 0.49%, down by 2.97% compared to the previous period[8] - Total operating revenue for the current period was ¥72,550,329.09, a decrease of 6.1% from ¥77,972,604.90 in the previous period[38] - Net profit for the current period was ¥2,167,935.28, a significant decline of 88.3% compared to ¥18,508,847.19 in the previous period[39] - Basic earnings per share decreased to ¥0.0153 from ¥0.1322 in the previous period, reflecting a decline of 88.4%[40] - Total operating revenue for the current period is CNY 222,740,815.96, a decrease of 1.3% from CNY 227,270,208.22 in the previous period[44] - Net profit for the current period is CNY 29,427,791.37, down 50.3% from CNY 59,260,014.40 in the previous period[46] Assets and Liabilities - Total assets increased by 4.05% to CNY 729,067,780.40 compared to the end of the previous year[8] - The company's total liabilities as of September 30, 2017, were CNY 175,788,470.53, compared to CNY 148,304,997.43 at the beginning of the period[32][33] - The company's cash and cash equivalents increased to CNY 417,850,229.34 from CNY 414,873,165.46 at the beginning of the period[30] - Accounts receivable rose to CNY 30,064,538.94 from CNY 20,011,106.67, indicating a growth of approximately 50%[30] - The company reported an increase in inventory to CNY 19,182,908.75 from CNY 17,642,057.24, reflecting a growth of about 8.7%[30] - The company’s equity attributable to shareholders reached CNY 553,279,309.87, slightly up from CNY 552,361,356.97 at the beginning of the period[33] Cash Flow - The company reported a net cash flow from operating activities of CNY 59,074,892.81, an increase of 4.01% year-to-date[8] - The net cash flow from operating activities for the third quarter was CNY 59,074,892.81, an increase from CNY 56,797,789.12 in the same period last year, representing a growth of approximately 4.5%[52] - The total cash outflow from operating activities amounted to CNY 239,185,923.00, compared to CNY 210,110,307.55 in the previous year, indicating an increase of about 13.8%[52] - The net cash flow from investing activities was negative CNY 148,072,103.93, a significant decline from a positive CNY 221,016,766.03 in the same period last year[52] - The cash and cash equivalents at the end of the period were CNY 237,600,229.34, down from CNY 355,978,892.31 at the end of the same quarter last year, a decrease of about 33.2%[53] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,337[11] - The largest shareholder, Fujian Aohua Group Co., Ltd., holds 24.72% of the shares, amounting to 35,068,651 shares[11] - There were no significant changes in the shareholding structure or any repurchase transactions among the top shareholders during the reporting period[12] Strategic Initiatives - The company launched the new drug Tenofovir in July 2017, incurring promotional and market development expenses of CNY 11.2 million during the reporting period, contributing to the decline in performance[16] - Research and development expenses increased by CNY 11.7 million compared to the same period last year, reflecting the company's commitment to R&D[16] - The company received production registration certificates for Tenofovir, becoming the first domestic company approved for this hepatitis B treatment, enhancing its market competitiveness[19] - The company plans to raise up to CNY 100 million through a non-public offering to fund the construction of an international pharmaceutical base and a children's hospital[20] - The actual controller and chairman, Li Guoping, announced a share buyback plan, intending to purchase shares worth no less than CNY 30 million at a price not exceeding CNY 60 per share[20] - The company established a wholly-owned subsidiary to open a high-end medical institution in collaboration with United Family Healthcare, enhancing its service offerings[21] - A strategic cooperation agreement was signed with Reproductive Genetic Innovations, LLC to establish a world-class genetic research center in China, expanding the company's service capabilities in reproductive health[21] - The company established a wholly-owned subsidiary, Guangshengtang Assisted Reproductive Overseas Co., Ltd., in Hong Kong to invest in leading overseas assisted reproductive medical institutions and enhance its industry chain layout in genetic research and reproductive science[22] - The new liver cancer targeted drug GST-HG161 has made significant progress, with the identification of a preclinical candidate compound that exhibits notable efficacy, good target selectivity, high safety, and strong druggability[22] Expenses - Total operating costs increased to ¥72,186,939.87, up 30.4% from ¥55,343,294.67 in the previous period[38] - The company reported a significant increase in sales expenses, which reached ¥34,636,931.96, up 29.0% from ¥26,840,044.99[39] - Management expenses increased to CNY 70,202,375.91, up 28.2% from CNY 54,743,325.87 in the previous period[45]